CARLHA: Radiotherapy Plus Hormone Therapy in Biochemically-relapsing Prostate Cancer Patients Following Surgery
Study Details
Study Description
Brief Summary
As there is no prospective data on the combination of abiraterone and salvage radiotherapy, the aim of this study is to further evaluate the safety profile of abiraterone acetate plus prednisone in patients with prostate cancer who are biochemically relapsing after surgery and undergo salvage radiotherapy with 6-months LH-RH agonist.
The investigators hypothesize that the toxicity profile of both treatments should not potentiate each other. This study will also provide preliminary data on the efficacy of this combination.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1/Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: abiraterone Abiraterone acetate (three dose levels in phase I) + prednisone (10mg/day)+LHRH + Radiotherapy |
Drug: Abiraterone
Abiraterone acetate 1000mg/day + prednisone alone for one month before initiating the sequence of radiotherapy
|
Outcome Measures
Primary Outcome Measures
- to determine the maximum tolerated dose and the phase II recommended dose of abiraterone acetate treatment plus prednisone and LH-RH agonist combined with prostate radiotherapy [within 11 weeks after Radiotherapy initiation]
Secondary Outcome Measures
- To evaluate the 3-year biochemical relapse-free survival [3 years]
Other Outcome Measures
- overall safety profile [3 years]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Histologically confirmed prostate adenocarcinoma
-
The patients should have undergone only surgery for localized prostate adenocarcinoma: pT2, pT3 or pT4 with bladder neck involvement
-
pN0: negative lymphadenectomy at the time of prostatectomy
-
At inclusion the patients should have no clinical signs of progressive disease and should be M0 (bone and pelvic scans).
-
≥ 18 years of age with life expectancy ≥ 10 years
-
Performance Status (ECOG) ≤ 1
-
PSA ≤ 0.1 ng/ml after prostatectomy (dosage performed within 2 months after surgery)
-
PSA ≥ 0.2 ng/ml et ≤ 2 ng/ml at the time of inclusion
-
Elevation of PSA over three consecutive assays performed in the same laboratory, with a minimal interval of two months between assays, (PSA nadir level followed by two other progressive assays)
-
At least 6 months between surgery and biochemical relapse
-
Serum potassium ≥ 3.5 mmol/L in the 72 hours before first dose of abiraterone acetate
-
Serum creatinine < 1.5 x ULN or a calculated creatinine clearance ≥ 60 mL/min
-
Liver function:
Serum bilirubin < 1.5 x ULN (except for patients with documented Gilbert's disease) AST and ALT < 2.5 x ULN
-
Patients must be affiliated to a Social Security System.
-
Patient information and written informed consent form signed for both principal and additional research
-
Patients must be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures
Exclusion Criteria:
-
pN1: histologically-proven lymph node involvement at initial lymphadenectomy
-
Histology other than adenocarcinoma
-
Previous hormone therapy including prior therapy with ketoconazole or other CYP17 inhibitor(s) for prostate cancer.
-
Patients being treated within the last 14 days prior to inclusion with drugs recognized as being strong inhibitors or inducers of the isoenzyme CYP3A4 (Clarithromycin, Ketoconazole, Itraconazole, Voriconazole, Ritanovir, see appendix 11) or requiring those treatments during the study
-
Active or symptomatic viral hepatitis or chronic liver disease
-
Surgical or chemical castration
-
History of cancer, with the exception of basal cell carcinoma or any other cancer treated in the 5 years before inclusion and in complete remission.
-
Previous pelvic radiotherapy
-
Uncontrolled hypertension (defined as systolic BP ≥ 140 mmHg or diastolic BP ≥ 90 mmHg). Patients with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive therapy (see appendix 10 for mandatory BP measurement guidelines)
-
Severe and moderate hepatic impairment (Child-Pugh class B and C)
-
Patients with severe and/or uncontrolled medical disease which could compromise participation in the study, such as, but not limited to:
Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or New York Heart Association (NYHA) Class III or IV heart disease or cardiac ejection fraction measurement of < 50 % at baseline
-
Known hypersensitivity to any of the study drugs or excipients.
-
Galactosemia, Glucose-galactose malabsorption or lactase deficiency
-
Patients with any psychological, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.
-
Individual deprived of liberty or placed under the authority of a tutor.
-
Patients already included in another therapeutic trial with an experimental drug or having been given an experimental drug within a period of 30 days.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Institut Bergonié | Bordeaux | France | ||
| 2 | Centre François Baclesse | Caen | France | ||
| 3 | Centre Georges François Leclerc | Dijon | France | ||
| 4 | Centre Leon Berard | Lyon | France | 69373 | |
| 5 | Institut de Cancérologie de l'ouest/René Gauducheau | Saint-Herblain | France | 44805 |
Sponsors and Collaborators
- UNICANCER
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- GEP12-UC-0101/1104
- 2011-004831-30